An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix

Andrzej P. Kudelka, Rodger Winn, Creighton L. Edwards, G. Downey, Harvey Greenberg, S. R. Dakhil, Ralph S. Freedman, Salvatore LoCoco, J. Umbreit, James E. Delmore, Susan Arbuck, Evelyne Loyer, Patsy Gacrama, Rebecca Fueger, John J. Kavanagh

Research output: Contribution to journalArticle

53 Scopus citations

Abstract

Thirty-two evaluable patients with squamous cell cancer of the cervix were treated with i.v. paclitaxel 250 mg/m2 over 3 h every 21 days. They received standard premedications and granulocyte colony stimulating factor (G-CSF) support (5 μg/kg/day). Median (range) age was 49 (29-81) years and performance status Zubrod was 1 (0-2). One patient had a complete response and seven patients had a partial response (25%, 95% CI 8-38%). The median survival was 7.3 months. Granulocytopenia was brief and non-cumulative. G-CSF was used for a median (range) of 8 (1-15) days per cycle. In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support.

Original languageEnglish (US)
Pages (from-to)657-661
Number of pages5
JournalAnti-Cancer Drugs
Volume8
Issue number7
DOIs
StatePublished - Oct 6 1997
Externally publishedYes

Keywords

  • Cervix cancer
  • Granulocyte colony stimulating factor
  • Paclitaxel

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Cancer Research

Fingerprint Dive into the research topics of 'An update of a phase II study of paclitaxel in advanced or recurrent squamous cell cancer of the cervix'. Together they form a unique fingerprint.

Cite this